Testing two medications together for advanced lung cancer

This is a research study testing whether two medications—osimertinib and savolitinib—work better together than existing treatments for people with advanced lung cancer that has become resistant to previous therapies. You would take both medications by mouth daily. The study is looking for people whose cancer has a specific genetic change called low copy number MET amplification and who have already tried at least three other treatment approaches.

When lung cancer stops responding to osimertinib (a common targeted therapy), patients often have limited options left. Researchers believe that adding a second medication called savolitinib might help overcome this resistance and give patients more time before their cancer progresses.